<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">HJBM</journal-id><journal-title-group><journal-title>Hans Journal of Biomedicine</journal-title></journal-title-group><issn pub-type="epub">2161-8976</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/HJBM.2021.113023</article-id><article-id pub-id-type="publisher-id">HJBM-44248</article-id><article-categories><subj-group subj-group-type="heading"><subject>HJBM20210300000_93345044.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  Cdc42表达载体构建及协同药物对细胞迁移的影响
  Construction of Cdc42 Expression Vector and the Effect of It Coordinating with the Peptidomimetics on Cell Migration
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>武</surname><given-names>诺帆</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>罗</surname><given-names>苗苗</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陈</surname><given-names>尧禹</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>汪</surname><given-names>香荣</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陈</surname><given-names>雯雯</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>鹏</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陈</surname><given-names>俊</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>武汉科技大学生物工程系，湖北 武汉</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>01</day><month>06</month><year>2021</year></pub-date><volume>11</volume><issue>03</issue><fpage>176</fpage><lpage>185</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  为了研究Cdc42协同拟肽化合物对A549细胞迁移的影响，构建携带红、绿荧光报告基因的Cdc42真核表达载体，转染293T细胞，观察基因表达情况；测定实验用化合物(PMC4)对A549细胞的毒性；进一步将Cdc42转染高迁移率的A549细胞，然后用拟肽化合物刺激，通过细胞划痕实验，初步检测Cdc42协同拟肽化合物对A549细胞迁移的影响。结果表明：本实验成功构建了Cdc42异构体基因的真核表达载体pGFP-cdc42-2、pGFP-cdc42-3、pRed-cdc42-2、pRed-cdc42-3，转染293T细胞效率约为90%；10 μmol/L的拟肽化合物对A549细胞毒性微弱，拟肽药物分子末端对位上的取代基为氟时，其对细胞迁移具有促进作用，过表达Cdc42时，Cdc42协同药物使细胞迁移进一步增加，具体机制有待进一步研究。
   In order to study the effect of Cdc42 coordinating with the peptidomimetics on the migration of A549 cells, the Cdc42 eukaryotic expression vectors harboring fluorescent reporter genes were constructed and transfected into 293T cells. The expression of Cdc42 was observed by fluorescence microscopy. The cytotoxicity of the compound (PMC4) on A549 cells was tested. The Cdc42 genes were further ex- pressed in the high mobility cells A549 and the compound was added. The cooperation effect of Cdc42 with the compound on the cell migration was investigated by cell wound scratch assay. The results showed that the eukaryotic expression vectors of Cdc42 isoform genes were successfully constructed named pGFP-cdc42-2, pGFP-cdc42-3, pRed-cdc42-2, pRed-cdc42-3 respectively. These recombinants plasmids were transfected into 293T cells and the transfection ef-ficiency was about 90%. 10 μmol/L peptidomimetic compounds showed weak toxicity to A549 cells. When the substituent group at the terminal para-position of the peptidomimetic drug molecule is F (fluorin), it can increase the migration of A549 cells. While the Cdc42 gene was over-expressed in A549 cells and the cell migration rate was enhanced furtherly. More studies and results need to be carried out to reveal the detail mechanism.
 
</p></abstract><kwd-group><kwd>Cdc42基因，A549细胞，细胞划痕实验，细胞迁移，拟肽化合物, Cdc42 gene</kwd><kwd> A549 Cells</kwd><kwd> Cell Wound Scratch Assay</kwd><kwd> Cell Migration</kwd><kwd> Peptidomimetic Compounds</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>为了研究Cdc42协同拟肽化合物对A549细胞迁移的影响，构建携带红、绿荧光报告基因的Cdc42真核表达载体，转染293T细胞，观察基因表达情况；测定实验用化合物(PMC4)对A549细胞的毒性；进一步将Cdc42转染高迁移率的A549细胞，然后用拟肽化合物刺激，通过细胞划痕实验，初步检测Cdc42协同拟肽化合物对A549细胞迁移的影响。结果表明：本实验成功构建了Cdc42异构体基因的真核表达载体pGFP-cdc42-2、pGFP-cdc42-3、pRed-cdc42-2、pRed-cdc42-3，转染293T细胞效率约为90%；10 μmol/L的拟肽化合物对A549细胞毒性微弱，拟肽药物分子末端对位上的取代基为氟时，其对细胞迁移具有促进作用，过表达Cdc42时，Cdc42协同药物使细胞迁移进一步增加，具体机制有待进一步研究。</p></sec><sec id="s2"><title>关键词</title><p>Cdc42基因，A549细胞，细胞划痕实验，细胞迁移，拟肽化合物</p></sec><sec id="s3"><title>Construction of Cdc42 Expression Vector and the Effect of It Coordinating with the Peptidomimetics on Cell Migration<sup> </sup></title><p>Nuofan Wu, Miaomiao Luo, Yaoyu Chen, Xiangrong Wang, Wenwen Chen, Peng Wang, Jun Chen<sup>*</sup></p><p>Bioengineering Department, Wuhan University of Science and Technology, Wuhan Hubei</p><p><img src="//html.hanspub.org/file/8-1530180x4_hanspub.png?20210730083734858" /></p><p>Received: Jun. 11<sup>th</sup>, 2021; accepted: Jun. 25<sup>th</sup>, 2021; published: Jul. 29<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/8-1530180x6_hanspub.png?20210730083734858" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>In order to study the effect of Cdc42 coordinating with the peptidomimetics on the migration of A549 cells, the Cdc42 eukaryotic expression vectors harboring fluorescent reporter genes were constructed and transfected into 293T cells. The expression of Cdc42 was observed by fluorescence microscopy. The cytotoxicity of the compound (PMC4) on A549 cells was tested. The Cdc42 genes were further ex- pressed in the high mobility cells A549 and the compound was added. The cooperation effect of Cdc42 with the compound on the cell migration was investigated by cell wound scratch assay. The results showed that the eukaryotic expression vectors of Cdc42 isoform genes were successfully constructed named pGFP-cdc42-2, pGFP-cdc42-3, pRed-cdc42-2, pRed-cdc42-3 respectively. These recombinants plasmids were transfected into 293T cells and the transfection efficiency was about 90%. 10 μmol/L peptidomimetic compounds showed weak toxicity to A549 cells. When the substituent group at the terminal para-position of the peptidomimetic drug molecule is F (fluorin), it can increase the migration of A549 cells. While the Cdc42 gene was over-expressed in A549 cells and the cell migration rate was enhanced furtherly. More studies and results need to be carried out to reveal the detail mechanism.</p><p>Keywords:Cdc42 gene, A549 Cells, Cell Wound Scratch Assay, Cell Migration, Peptidomimetic Compounds</p><disp-formula id="hanspub.44248-formula34"><graphic xlink:href="//html.hanspub.org/file/8-1530180x7_hanspub.png?20210730083734858"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/8-1530180x8_hanspub.png?20210730083734858" /> <img src="//html.hanspub.org/file/8-1530180x9_hanspub.png?20210730083734858" /></p></sec><sec id="s5"><title>1. 引言</title><p>Cdc42全称为细胞分裂周期蛋白(cell division cycle 42, Cdc42)，属于Rho GTPases家族蛋白之一，在肿瘤转移和恶化中扮演极其重要的角色。由于Cdc42在细胞分裂调节和肌动蛋白细胞骨架重排中起重要作用，因此细胞生长、迁移、侵袭、极性和粘附都与Cdc42相关 [<xref ref-type="bibr" rid="hanspub.44248-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.44248-ref2">2</xref>]。Cdc42在细胞信号通路中充当分子开关，在细胞皮层之间从非活性的GDP结合形式转化为有活性的GTP结合形式，进而激活下游效应分子，以此对细胞外信号做出生理学应答 [<xref ref-type="bibr" rid="hanspub.44248-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.44248-ref4">4</xref>]。在癌细胞细胞中过表达Cdc42突变体Cdc42G12V，会造成细胞生长阻滞，这说明Cdc42致细胞恶性转化的潜能与Cdc42-GTP和Cdc42-GDP之间的动态平衡有关 [<xref ref-type="bibr" rid="hanspub.44248-ref5">5</xref>]。另外，Cdc42也参与了抗癌药物抗性的产生，例如乳腺癌 [<xref ref-type="bibr" rid="hanspub.44248-ref6">6</xref>]。与GTPases家族的Rho和Rac蛋白一样，Cdc42也是潜在的研发抗癌药物的靶标 [<xref ref-type="bibr" rid="hanspub.44248-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.44248-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.44248-ref9">9</xref>]，MiRNA和靶向Cdc42的小分子药物以及关联的信号通路，通过抑制Cdc42异常的过表达从而减缓癌细胞转移，为抗肿瘤药物的开发提供新的策略 [<xref ref-type="bibr" rid="hanspub.44248-ref10">10</xref>]。近年来针对乳腺癌的治疗，已研发数种以Cdc42为靶标的治疗药物 [<xref ref-type="bibr" rid="hanspub.44248-ref11">11</xref>] - [<xref ref-type="bibr" rid="hanspub.44248-ref18">18</xref>]。拟肽是一类利用人工合成的物质模拟天然多肽的结构，或者利用构象性模板诱导相邻的多肽序列而形成的具有特异结构的化合物 [<xref ref-type="bibr" rid="hanspub.44248-ref19">19</xref>]。我们前期药物合成实验，获得了一些拟肽化合物。本研究拟构建含荧光报告基因的Cdc42真核表达载体，并初步探讨Cdc42协同拟肽化合物对细胞迁移的影响。</p></sec><sec id="s6"><title>2. 实验材料与方法</title><sec id="s6_1"><title>2.1. 试剂和细胞</title><p>真核表达载体pDsRed-C1、pEGFP-C1、大肠杆菌感受态细胞DH5α、A549细胞和293T细胞均为本实验室保存。培养细胞所用材料均购自Gibico公司；限制性核酸内切酶购自Thermo公司；T4 DNA ligase购自Takara公司；Ex Taq master Mix购自康为世纪生物公司；CCK8试剂盒购自日本同仁化学研究所，质粒提取及胶回收试剂盒均为Omega公司产品；PCR引物合成及DNA测序由擎科生物公司完成。PMC4为我们前期合成，其结构如图1，在R1位置处为-F取代基。</p><p>图1. PMC4分子结构示意图</p></sec><sec id="s6_2"><title>2.2. 携带红、绿荧光报告基因的真核表达载体的构建</title><p>以pT-cdc42-2/3质粒为模板，分别使用其对应的引物(表1) PCR扩增目的基因Cdc42-2/3，PCR产物经EcoR I和BamH I两种酶消化后，连接到经相同酶切的真核质粒载体pEGFP-C1和pDsred-C1中，所得质粒命名为pGFP-cdc42-2、pGFP-cdc42-3、pRed-cdc42-2、pRed-cdc42-3。经菌液PCR、质粒PCR以及重组质粒双酶切鉴定分析其正确性。最后将鉴定成功的重组质粒送去测序公司精确鉴定。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Main primer</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >引物名称</th><th align="center" valign="middle" >引物序列(5'&quot;3')</th></tr></thead><tr><td align="center" valign="middle" >Red-cdc42-2-F Red-cdc42-3-F</td><td align="center" valign="middle" >GGAGAATTCATGCAGACAATTAAGTGTGTTGTTG EcoR I</td></tr><tr><td align="center" valign="middle" >Red-cdc42-2-R Red-cdc42-3-R</td><td align="center" valign="middle" >CGGGATCCTCATAGCAGCACACACCTGCGG BamH I</td></tr><tr><td align="center" valign="middle" >GFP-cdc42-2-F</td><td align="center" valign="middle" >GGAGAATTCATGCAGACAATTAAGTGTGTTGTTG EcoR I</td></tr><tr><td align="center" valign="middle" >GFP-cdc42-2-R</td><td align="center" valign="middle" >CGGGATCCTTAGAATATACAGCACTTCCTTTTGG BamH I</td></tr><tr><td align="center" valign="middle" >GFP -cdc42-3-F</td><td align="center" valign="middle" >GGAGAATTCATGCAGACAATTAAGTGTGTTGTTG EcoR I</td></tr><tr><td align="center" valign="middle" >GFP-cdc42-3-R</td><td align="center" valign="middle" >CGGGATCC TCATAGCAGCACACACCTGCGG BamH I</td></tr></tbody></table></table-wrap><p>表1. 主要引物</p></sec><sec id="s6_3"><title>2.3. 重组质粒转染293T细胞</title><p>提取去内毒素的超纯重组质粒。将生长状态良好的293T细胞以每孔2 &#215; 10<sup>5</sup>个细胞种于6孔细胞培养板， 37 ℃ 培养过夜后使用聚乙烯亚胺(polyethylenimine, PEI)作为转染试剂，转染试剂用量DNA:PEI = 3:1，将重组质粒转染至293T细胞。转染6 h后换液，继续培养24 h。在454 nm波长蓝光激发下观察绿荧光，在556 nm波长的绿光激发下观察红荧光。</p></sec><sec id="s6_4"><title>2.4. CCK-8法检测拟肽化合物细胞毒性</title><p>用CCK-8法测定化合物对细胞的毒性，将A549细胞以每孔5 &#215; 10<sup>4</sup>个细胞种于取96孔板， 37 ℃ 过夜培养。待细胞完全贴壁后，在对照组加入1 μL DMSO溶液，在实验组加入1 μL不同浓度化合物溶液，控制终浓度为1 μmol/L、10 μmol/L、100 μmol/L，每组三个复孔。继续培养48 h，在每孔加入10 μL的CCK-8试剂，再次放入细胞培养箱中孵育1 h~2 h。取出细胞培养板，用多功能酶标仪在450 nm下测定吸光值。</p></sec><sec id="s6_5"><title>2.5. 细胞划痕法研究Cdc42协同化合物对细胞迁移的影响</title><p>培养A549细胞，种于6孔板，转染重组质粒，转染12 h后，用枪头尖端在细胞孔板中划3条平行直线，PBS冲洗去悬浮的细胞。添加化合物，控制试验浓度为10 μmol/L。分别在0 h，24 h，48 h于显微镜下观察细胞迁移情况，并拍照记录迁移距离，以便后期计算迁移率。</p></sec></sec><sec id="s7"><title>3. 实验结果与分析</title><sec id="s7_1"><title>3.1. 真核表达载体构建结果与分析</title><p>Cdc42基因扩增结果见图2，获得的基因片段长度与预期(576 bp)一致。扩增得到的目的片段、载体pEGFP-C1、pDsred-C1均用EcoR I和BamH I进行双酶切，检测结果见图3。双酶切后的目的基因在500 bp~750 bp之间，双酶切载体条带在5000 bp附近，初步判断双酶切是正确的。</p><p>图2. 目的基因Cdc42-2/3的扩增。(a)：从pT-Cdc42-2/3中扩增用于连接pEGFP-C1载体的Cdc42-2/3目的基因；(b)：从pT-Cdc42-2/3中扩增用于连接pDsred-C1载体的Cdc42-2/3目的基因；M：DNA Maker 2000；1~3：Cdc42-2基因；4~6：Cdc42-3基因</p><p>图3. 目的基因和载体的双酶切。(a)：目的基因和载体pEGFP-C1的双酶切；(b)：目的基因和载体pDsred-C1的双酶切；M：DNA Maker 5000；1：双酶切Cdc42-2；2：双酶切Cdc42-3；3：双酶切pEGFP-C1 (a图)、pDsred-C1 (b图)；4：pEGFP-C1 (a图)、pDsred-C1 (b图)</p><p>回收酶切产物，连接转化大肠杆菌，分别挑取单菌落进行菌落PCR鉴定，结果如图4，所构建的重组子均能扩增出目的大小的片段(576 bp)。提取重组质粒，结果见图5，重组质粒pGFP-cdc42-2、pGFP-cdc42-3、pRed-cdc42-2和pRed-cdc42-3均提取成功(重组质粒大小为5276 bp)，然后以重组质粒为模板，进行质粒PCR鉴定，结果见图6，均能扩增出目的大小的片段(576 bp)。</p><p>重组质粒进一步进行双切分析，结果如图7，可以看出，成功的切出了大小在567 bp左右的目的基因条带，可以得出Cdc42-2/3成功克隆到pEGFP-C1和pDsred-C1载体上。构建好的表达载体送去测序，</p><p>图4. 重组子菌落PCR鉴定。(a)：pGFP-cdc42-2、pGFP-cdc42-3重组子菌落PCR鉴定；(b)：pRed-cdc42-2、pRed-cdc42-3重组子菌落PCR鉴定；M：DNA Maker 2000；(a1)~(a3)：pGFP-cdc42-2重组子菌落PCR；(a4)~(a6)：pGFP-cdc42-3重组子菌落PCR；(b1)~(b3)：pRed-cdc42-2重组子菌落PCR；(b4)~(b6)：pRed-cdc42-3重组子菌落PCR</p><p>图5. 提取重组质粒DNA。(a)：提取pGFP-cdc42-2、pGFP-cdc42-3 重组质粒DNA；(b)：提取pRed-cdc42-2、pRed-cdc42-3 重组质粒DNA；M：DNA Maker 5000；(a1) &amp; (a2)：重组质粒pGFP-cdc42-2；(a3) &amp; (a4)：重组质粒pGFP-cdc42-3；(b1) &amp; (b2)：重组质粒pRed-cdc42-2；(b3) &amp; (b4)：重组质粒pRed-cdc42-3</p><p>图6. 以重组质粒为模板进行PCR鉴定。(a)：以pGFP-cdc42-2、pGFP-cdc42-3重组质粒DNA为模板进行PCR鉴定；(b)：以pRed-cdc42-2、pRed-cdc42-3重组质粒DNA为模板进行PCR鉴定；M：DNA Maker 2000；(a1) &amp; (b1)：以pT-cdc42-2为模板做PCR；(a2) &amp; (a3)：以pGFP-cdc42-2为模板做PCR；(a4) &amp; (b4)：以pT-cdc42-3为模板做PCR；(a5) &amp; (a6)：以pGFP-cdc42-3为模板做PCR；(b2) &amp; (b3)：以pRed-cdc42-2为模板做PCR；(b5) &amp; (b6)：以pRed-cdc42-3为模板做PCR</p><p>图7. 重组质粒双酶切鉴定。(a)：重组质粒pGFP-cdc42-2、pGFP-cdc42-3双酶切鉴定；(b)：重组质粒pRed-cdc42-2、pRed-cdc42-3双酶切鉴定M：DNA Maker 5000；A1&amp;B1：Cdc42-2片段双酶切；(a2)：pGFP-cdc42-2重组质粒双酶切；(a3)：pEGFP-C1空载体双酶切；(a4)：pGFP-cdc42-3重组质粒双酶切；(a5) &amp; (b5)：Cdc42-3片段双酶切；(b2)：pRed-cdc42-2重组质粒双酶切；(b3)：pDsRed-C1空载体双酶切；(b4)：pRed-cdc42-3重组质粒双酶切</p><p>测序结果与NCBI里面Cdc42比对分析，序列一致，没有碱基缺失与突变。通过以上鉴定分析可以得出，目的基因已经成功插入荧光表达载体中。</p></sec><sec id="s7_2"><title>3.2. 重组质粒转染293T细胞实验结果与分析</title><p>将重组质粒分别转染293T细胞，转染结果见图8，单独的pEGFP-C1转染见图8(b)，转染效率高达90%。pGFP-cdc42-2、pGFP-cdc42-3单独转染293T细胞见图8(d)、图8(f)，均能有效表达。没有单独的pEGFP-C1亮(见图8(b))，这可能是Cdc42-2/3蛋白与GFP蛋白形成融合蛋白折叠的过程中，Cdc42-2/3遮盖了部分GFP所致。</p><p>图8. 重组质粒转染293T细胞。(a) &amp; (b)：pEGFP-C1转染293T细胞；(c) &amp; (d)：pGFP-cdc42-2转染293T细胞；(e) &amp; (f)：pGFP-cdc42-3转染293T细胞；(a)、(c)、(e) 图为白光；(b)、(e)、(f)图为激发光</p><p>携带红荧光基因报告基因的质粒转染293T细胞结果见图9，图9(h)是pDsRed单独转染293T细胞的情况。pRed-cdc42-2、pRed-cdc42-3分别转染293T细胞见图9(j)和图9(l)，观察到比较亮的红色荧光，与pGFP-cdc42-2 (见图9(d))相比，pRed-cdc42-2/3更有利于Cdc42的表达。</p><p>图9. 重组质粒转染293T细胞。(g) &amp; (h)：pDsRed-C1转染293T细胞；(i) &amp; (j)：pRed-cdc42-2转染293T细胞；(k) &amp; (l): pRed-cdc42-3转染293T细胞；(a)、(c)、(e)图为白光；(b)、(e)、(f)图为激发光</p><p>由图8和图9可以看出，Cdc42的同源异构体基因克隆至pDsRed-C1载体上的表达量要高于该基因克隆至pEGFP-C1载体，这表明后续实验可以采用红荧光报告基因系列重组质粒。</p></sec><sec id="s7_3"><title>3.3. CCK-8法测定化合物细胞毒性实验结果与分析</title><p>在不同拟肽化合物浓度下，用CCK-8法测定的细胞活度结果见表2。所以后续细胞实验时，选择了对细胞毒性较弱的10 μmol/L拟肽化合物浓度，作为试验工作浓度。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Cell viability assay by CCK-</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >拟肽化合物4浓度</th><th align="center" valign="middle" >0 μmol/L (DMSO对照)</th><th align="center" valign="middle" >1 μmol/L</th><th align="center" valign="middle" >10 μmol/L</th><th align="center" valign="middle" >100 μmol/L</th></tr></thead><tr><td align="center" valign="middle" >A549细胞活度</td><td align="center" valign="middle" >1.00</td><td align="center" valign="middle" >0.98</td><td align="center" valign="middle" >0.95</td><td align="center" valign="middle" >0.82</td></tr></tbody></table></table-wrap><p>表2. CCK-8法测定细胞活度表</p></sec><sec id="s7_4"><title>3.4. Cdc42协同化合物对细胞迁移的影响实验结果与分析</title><p>将重组质粒转染至迁移能力较强的A549细胞，进行细胞划痕实验。根据细胞划痕实验结果，制作细胞迁移对比图，如图10所示。通过对比分析表3和图10，可以得出以下结论：</p><p>① 细胞中过表达基因Cdc42后，细胞迁移率提高；</p><p>② 加拟肽化合物刺激细胞后，细胞迁移率同样是升高的；</p><p>③ 细胞中过表达基因Cdc42，同时用化合物刺激，细胞迁移率更大。</p><p>图10. 细胞划痕实验</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> The results of Cell wound scratch assa</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >是否加化合物</th><th align="center" valign="middle" >转染质粒</th><th align="center" valign="middle" >48 h细胞迁移率(%)</th><th align="center" valign="middle" >促进系数</th></tr></thead><tr><td align="center" valign="middle" >是</td><td align="center" valign="middle" >pEGFP-C1</td><td align="center" valign="middle" >44.27</td><td align="center" valign="middle" >1.18</td></tr><tr><td align="center" valign="middle" >是</td><td align="center" valign="middle" >pGFP-cdc42-2</td><td align="center" valign="middle" >47.79</td><td align="center" valign="middle" >1.27</td></tr><tr><td align="center" valign="middle" >否</td><td align="center" valign="middle" >pDsred-C1</td><td align="center" valign="middle" >37.67</td><td align="center" valign="middle" >1.00</td></tr><tr><td align="center" valign="middle" >否</td><td align="center" valign="middle" >pRed-cdc42-2</td><td align="center" valign="middle" >39.13</td><td align="center" valign="middle" >1.04</td></tr><tr><td align="center" valign="middle" >否</td><td align="center" valign="middle" >pRed-cdc42-3</td><td align="center" valign="middle" >39.59</td><td align="center" valign="middle" >1.05</td></tr></tbody></table></table-wrap><p>表3. 细胞划痕实验结果</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>Cdc42作为一类小GTPases，参与了众多的细胞生理过程。当有胞外信号刺激细胞时，胞内的GEFs会被激活，活化的GEFs催化GDP从Cdc42上解离，GTP与Cdc42结合，Cdc42由于GTP的结合而被活化，活化的Cdc42与效应分子结合，导致多种信号级联的激活，调节细胞的增殖、存活、侵袭和迁移等过程 [<xref ref-type="bibr" rid="hanspub.44248-ref2">2</xref>]。本研究中用的拟肽化合物PCM4，由本实验合成，针对的靶标是细胞膜上的整联蛋白。实验结果表明，过表达Cdc42后，细胞迁移率提高，当添加PCM4后，细胞迁移率进一步增强，推测PCM4可能在胞外与膜整联蛋白结合，刺激胞内Cdc42的活化，进而通过Cdc42与效应分子结合，引起通过Cdc42介导的信号通路的开启，进而使细胞迁移率增强，具体机制有待于进一步研究。</p></sec><sec id="s9"><title>致 谢</title><p>感谢全国大学生创新创业大赛项目(201710488013)的资助；感谢武汉科技大学大学生创新创业大赛项 目(201710488013)的资助；感谢湖北大学生物催化与酶工程国家重点实验室开放基金(SKLBEE2018002) 的资助。</p></sec><sec id="s10"><title>文章引用</title><p>武诺帆,罗苗苗,陈尧禹,汪香荣,陈雯雯,王 鹏,陈 俊. Cdc42表达载体构建及协同药物对细胞迁移的影响Construction of Cdc42 Expression Vector and the Effect of It Coordinating with the Peptidomimetics on Cell Migration[J]. 生物医学, 2021, 11(03): 176-185. https://doi.org/10.12677/HJBM.2021.113023</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.44248-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Maldonado, M.D.M., Medina, J.I., Velazquez, L., et al. (2020) Targeting Rac and Cdc42 GEFs in Metastatic Cancer. Frontiers in Cell and Developmental Biology, 8, 201. &lt;br&gt;https://doi.org/10.3389/fcell.2020.00201</mixed-citation></ref><ref id="hanspub.44248-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Melendez, J., Grogg, M. and Zheng, Y. (2011) Signaling Role of Cdc42 in Regulating Mammalian Physiology. The Journal of Biological Chemistry, 286, 2375-2381. &lt;br&gt;https://doi.org/10.1074/jbc.R110.200329</mixed-citation></ref><ref id="hanspub.44248-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Stengel, K. and Zheng, Y. (2011) Cdc42 in Oncogenic Transformation, Invasion, and Tumorigenesis. Bone, 23, 1415-1423. &lt;br&gt;https://doi.org/10.1016/j.cellsig.2011.04.001</mixed-citation></ref><ref id="hanspub.44248-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Sinha, S. and Yang, W. (2008) Cellular Signaling for Activation of Rho GTPase Cdc42. Cell Signal, 20, 1927-1934.  
&lt;br&gt;https://doi.org/10.1016/j.cellsig.2008.05.002</mixed-citation></ref><ref id="hanspub.44248-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Xiao, X.H., Lv, L.C., Duan, J., et al. (2018) Regulating Cdc42 and Its Signaling Pathways in Cancer: Small Molecules and MicroRNA as New Treatment Candidates. Molecules, 23, 787-808. &lt;br&gt;https://doi.org/10.3390/molecules23040787</mixed-citation></ref><ref id="hanspub.44248-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, Y., Li, J., Lai, X.N., et al. (2019) Focus on Cdc42 in Breast Cancer: New Insights, Target Therapy Development and Non-Coding RNAs. Cells, 8, 146. &lt;br&gt;https://doi.org/10.3390/cells8020146</mixed-citation></ref><ref id="hanspub.44248-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Aspenström, P. (2018) Activated Rho GTPases in Cancer—The Beginning of a New Paradigm. International Journal of Molecular Sciences, 19, 3949. &lt;br&gt;https://doi.org/10.3390/ijms19123949</mixed-citation></ref><ref id="hanspub.44248-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Svensmark, J.H. and Brakebusch, C. (2019) Rho GTPases in Cancer: Friend or Foe? Oncogene, 38, 7447-7456.  
&lt;br&gt;https://doi.org/10.1038/s41388-019-0963-7</mixed-citation></ref><ref id="hanspub.44248-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Porazinski, S., Parkin, A. and Pajic, M. (2020) Rho-ROCK Signaling in Normal Physiology and as a Key Player in Shaping the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 1223, 99-127.  
&lt;br&gt;https://doi.org/10.1007/978-3-030-35582-1_6</mixed-citation></ref><ref id="hanspub.44248-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, M., Guo, W., Qian, J., et al. (2016) Negative Regulation of Cdc42 Expression and Cell Cycle Progression by miR-29A in Breast Cancer. Open Medicine, 11, 78-82. &lt;br&gt;https://doi.org/10.1515/med-2016-0015</mixed-citation></ref><ref id="hanspub.44248-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Kharbanda, S., Saxena, S., Yoshida, K., et al. (2000) Translocation of SAPK/JNK to Mitochondria and Interaction with Bcl-x(L) in Response to DNA Damage. Journal of Biological Chemistry, 275, 322-327.  
&lt;br&gt;https://doi.org/10.1074/jbc.275.1.322</mixed-citation></ref><ref id="hanspub.44248-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Schreiber, M., Kolbus, A., Piu, F., et al. (1999) Control of Cell Cycle Progression by c-Jun Is p53 Dependent. Genes &amp; Development, 13, 607-619. &lt;br&gt;https://doi.org/10.1101/gad.13.5.607</mixed-citation></ref><ref id="hanspub.44248-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, Y., Jiang, L., Qu, X.C., et al. (2010) Expression of Cdc42 in Adriamycin-Sensitivity and Adriamycin-Resistance MCF-7 Human Breast Cancer Cell Line. Chinese Journal of General Surgery, 19, 493-496.</mixed-citation></ref><ref id="hanspub.44248-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Schiff, R., Massarweh, S.A., Shou, J., et al.(2004) Cross-Talk between Estrogen Receptor and Growth Factor Pathways as a Molecular Target for Overcoming Endocrine Resistance. Clinical Cancer Research, 10, 331s-336s.  
&lt;br&gt;https://doi.org/10.1158/1078-0432.CCR-031212</mixed-citation></ref><ref id="hanspub.44248-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Azios, N.G., Krishnamoorthy, L., Harris, M., et al. (2007) Estrogen and Resveratrol Regulate Rac and Cdc42 Signaling to the Actin Cytoskeleton of Metastatic Breast Cancer Cells. Neoplasia, 9, 147-158. &lt;br&gt;https://doi.org/10.1593/neo.06778</mixed-citation></ref><ref id="hanspub.44248-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Gao, Y., Xing, J., Streuli, M., et al. (2001) Trp(56) of rac1 Specifies Interaction with a Subset of Guanine Nucleotide Exchange Factors. Journal of Biological Chemistry, 276, 47530-47541. &lt;br&gt;https://doi.org/10.1074/jbc.M108865200</mixed-citation></ref><ref id="hanspub.44248-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Humphries-Bickley, T., Castillo-Pichardo, L., Hernandez-O’Farrill, E., et al. (2017) Characterization of a Dual Rac/Cdc42 Inhibitor MBQ-167 in Metastatic Cancer. Molecular Cancer Therapeutics, 16, 805-818.  
&lt;br&gt;https://doi.org/10.1158/1535-7163.MCT-16-0442</mixed-citation></ref><ref id="hanspub.44248-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Frost, J.A., Swantek, J.L., Stippec, S., et al. (2000) Stimulation of NFkappa B Activity by Multiple Signaling Pathways Requires PAK1. Journal of Biological Chemistry, 275, 19693-19699. &lt;br&gt;https://doi.org/10.1074/jbc.M909860199</mixed-citation></ref><ref id="hanspub.44248-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">涂国刚, 李少华, 黄惠明, 等. 小分子拟肽类氨肽酶N抑制剂的合成及初步活性[J]. 中国药物化学杂志, 2008(5): 345-349.</mixed-citation></ref></ref-list></back></article>